Drugs / LAVA-051
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04887259 | Jul 2021 → Sep 2023 | B-cell chronic lymphocytic leukemia, acute myeloid leukemia, plasma cell myeloma | Lava Therapeutics | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-03-10 | Lava Therapeutics | Results LAVA Therapeutics B.V. to Present Preclinical Findings Supporting Anti-Tumor Activity of Lead Clinical Candidate LAVA-051 at the American Association for Cancer Research (AACR) Virtual 2021 Annual Meeting lavatherapeutics.com ↗
LAVA-051 exerted substantial antitumor activity against patient derived acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) cells that express CD1d. |
All press releases naming this drug 1 release
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LAVA-051 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04887259 ↗ |
| Route | Intravenous | “administered via intravenous (IV) infusion” NCT04887259 ↗ |